Anticoagulants for acute ischaemic stroke
Cochrane Database of Systematic ReviewsPublished 8 October 2008Open access
Peter Sandercock, Carl Counsell, Ayeesha Kamran Kamal
Citations347
SJR quartileQ1
SJR score1.62
SNIP2.04
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis and pulmonary embolism, but increased bleeding risk, and the data do not support the routine use of any the currently available anticoAGulants in acute ischaemic stroke.
Abstract
Since the last version of the review, no new relevant studies have been published and so there is no additional information to change the conclusions. Early anticoagulant therapy is not associated with net short- or long-term benefit in people with acute ischaemic stroke. Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis and pulmonary embolism, but increased bleeding risk. The data do not support the routine use of any of the currently available anticoagulants in acute ischaemic stroke.
Keywords
Medicine
BMJBias in meta-analysis detected by a simple, graphical test
56,268 Citations1997Matthias Egger, George Davey Smith +2 more
Funnel plots, plots of the trials' effect estimates against sample size, are skewed and asymmetrical in the presence of publication bias and other biases Funnel plot asymmetry, measured by regression analysis, predicts discordance of results when meta-analyses are compared with single large trials.
The LancetGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
14,264 Citations2012Rafael Lozano, Mohsen Naghavi +189 more
The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex, using the Cause of Death Ensemble model.
Cerebrovascular DiseasesAspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
11,556 Citations2014Qinghua Zhang, Chao Wang +6 more
Short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events and the clinical applicability of the findings of this systematic review needs to be confirmed in future clinical trials.
The LancetDisability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
9,004 Citations2012Christopher J L Murray, Theo Vos +360 more
The results for 1990 and 2010 supersede all previously published Global Burden of Disease results and highlight the importance of understanding local burden of disease and setting goals and targets for the post-2015 agenda taking such patterns into account.
StrokeGuidelines for the Early Management of Patients With Acute Ischemic Stroke
7,657 Citations2013Edward C. Jauch, Jeffrey L. Saver +13 more
These guidelines supersede the prior 2007 guidelines and 2009 updates and support the overarching concept of stroke systems of care and detail aspects of stroke care from patient recognition; emergency medical services activation, transport, and triage; through the initial hours in the emergency department and stroke unit.
BMJCollaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
6,893 Citations2002Antiplatelet Trialists Collaboration
Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardian infarctions, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation.
The LancetGlobal and regional burden of disease and risk factors, 2001: systematic analysis of population health data
5,629 Citations2006Alan D López, Colin Mathers +3 more
Despite uncertainties about mortality and burden of disease estimates, the findings suggest that substantial gains in health have been achieved in most populations, countered by the HIV/AIDS epidemic in Sub-Saharan Africa and setbacks in adult mortality in countries of the former Soviet Union.
The LancetGlobal and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010
3,925 Citations2013Valery L. Feigin, Mohammad H. Forouzanfar +18 more
Regional and country-specific estimates of stroke incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) lost by age group and country income level are calculated, to improve understanding of stroke determinants and burden worldwide.
BMJInteraction revisited: the difference between two estimates
3,135 Citations2003Douglas G. Altman, J Martin Bland
BMJCollaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
3,125 Citations1994Antiplatelet Trialists' Collaboration
There was no appreciable evidence that either a higher aspirin dose or any other antiplatelet regimen was more effective than medium dose aspirin in preventing vascular events, so in each of the four main high risk categories overall mortality was significantly reduced.
StrokeGuidelines for the Early Management of Adults With Ischemic Stroke
2,477 Citations2007Harold P. Adams, Gregory del Zoppo +14 more
The LancetThe International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke
1,890 Citations1997Peter Sandercock
Aspirinallocated patients had significantly fewer recurrent ischaemic strokes within 14 days with no significant excess of haemorrhagic strokes, so the reduction in death or non-fatal recurrent stroke with aspirin was significant.
Cochrane Database of Systematic ReviewsThrombolysis for acute ischaemic stroke
1,354 Citations2014Joanna M. Wardlaw, Veronica Murray +2 more
Thrombolytic therapy, mostly administered up to six hours after ischaemic stroke, significantly reduced the proportion of participants who were dead or dependent at three to six months after stroke and increased the risk of symptomatic intracranial haemorrhage.
New England Journal of MedicineReduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous Heparin
1,319 Citations1988Rory Collins, Alison Scrimgeour +2 more
Most deep-vein thromboses are subclinical and resolve completely when mobility is restored, although some do produce permanent valvular damage and chronic venous insufficiency, and a few, however, may travel to the lungs and, depending on how much of the pulmonary circulation is.
Journal of Neurology Neurosurgery & PsychiatryA prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project--1981-86. 2. Incidence, case fatality rates and overall outcome at one year of cerebral infarction, primary intracerebral and subarachnoid haemorrhage.
815 Citations1990John Bamford, Peter Sandercock +3 more
Generally more optimistic early prognosis in the Oxfordshire Community Stroke Project, particularly for cases of cerebral infarction, has important implications for the planning of clinical trials and for the expected impact that any treatment might have on the general population.
PubMedCollaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.
759 Citations1994
Reductions in vascular events were separately statistically significant in middle age and old age, in men and women, in hypertensive and normotensive patients, and in diabetic and nondiabetic patients, suggesting that longer treatment might well be more effective.
StrokeHemorrhagic and Ischemic Strokes Compared
560 Citations2009Klaus Kaae Andersen, Tom Skyhøj Olsen +2 more
Strokes are generally more severe in patients with HS within the first 3 months after stroke, and HS is associated with a considerable increase of mortality, which is specifically associated with the hemorrhagic nature of the lesion.
StrokeComplications After Acute Stroke
549 Citations1996Richard Davenport, Martin Dennis +2 more
Complications after acute stroke are common, confirming that stroke rehabilitation requires active and knowledgeable medical input and knowing the nature and timing of complications, together with the identification of high-risk patients, may be useful to those planning stroke services.
JAMALow Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled Trial
526 Citations1998The Publications Committee for the Trial of ORG in Acute Stroke Treatment Investigators
New England Journal of MedicineLow-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke
476 Citations1995R. Kay, Ka Sing Wong +9 more
For patients with ischemic stroke treated within 48 hours of the onset of symptoms, low-molecular-weight heparin was effective in improving outcomes at six months, and no significant differences among the groups in the occurrence of secondary outcomes were observed at 10 days.
Cochrane Database of Systematic ReviewsRandomisation to protect against selection bias in healthcare trials
440 Citations2011Jan Odgaard‐Jensen, Gunn Elisabeth Vist +8 more
The results of randomised and non-randomised studies sometimes differed and it is not generally possible to predict the magnitude, or even the direction, of possible selection biases and consequent distortions of treatment effects from studies with non- random allocation or controlled trials with inadequate or unclear allocation concealment.
PubMedThe International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.
411 Citations1997
The results suggest that if heparin is given in routine clinical practice, the dose should not exceed 5000 IU subcutaneously twice daily, and for aspirin, the IST suggests a small but worthwhile improvement at 6 months.
The LancetEffectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial
369 Citations2013Martin Dennis
IPC is an effective method of reducing the risk of DVT and possibly improving survival in a wide variety of patients who are immobile after stroke.
Cochrane Database of Systematic ReviewsAnticoagulants for acute ischaemic stroke
347 Citations2008Peter Sandercock, Carl Counsell +1 more
Treatment with anticoagulants reduced recurrent stroke, deep vein thrombosis and pulmonary embolism, but increased bleeding risk, and the data do not support the routine use of any the currently available anticoAGulants in acute ischaemic stroke.
The LancetThe efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison
327 Citations2007David G. Sherman, Gregory W. Albers +6 more
The results suggest that for patients with acute ischaemic stroke, enoxaparin is preferable to unfractionated heparin for venous thromboembolism prophylaxis in view of its better clinical benefits to risk ratio and convenience of once daily administration.
StrokeImmediate anticoagulation of embolic stroke: a randomized trial. Cerebral Embolism Study Group.
304 Citations1983
Data support immediate anticoagulation of nonhypertensive patients with embolic brain infarction who have no evidence of hemorrhage on CT performed 24-48 hours after stroke.
StrokeRisk of Early Death and Recurrent Stroke and Effect of Heparin in 3169 Patients With Acute Ischemic Stroke and Atrial Fibrillation in the International Stroke Trial
292 Citations2001Ritu Saxena, Stephanie Lewis +4 more
In patients with AF the absolute risk of early recurrent stroke is low, and there is no net advantage to treatment with heparin, but data do not support the widespread use of intensiveHeparin regimens in the acute phase of ischemic stroke associated with AF.
The Cochrane Database of Systematic ReviewsAntithrombotic drugs for carotid artery dissection
275 Citations2003Philippe Lyrer, Stefan T. Engelter
Cochrane Database of Systematic ReviewsAnticoagulation for cerebral sinus thrombosis
244 Citations2002J. Stam, Sebastiaan F. de Bruijn +1 more
Based upon the limited evidence available, anticoagulant treatment for cerebral sinus thrombosis appeared to be safe and was associated with a potentially important reduction in the risk of death or dependency which did not reach statistical significance.
Cochrane Database of Systematic ReviewsThrombolysis for acute ischaemic stroke
238 Citations2003Joanna M. Wardlaw, Gregory J. del Zoppo +2 more
Thrombolytic therapy increases deaths within the first seven to ten days, and deaths at final follow-up, and also significantly increases symptomatic and fatal intracranial haemorrhage following ischaemic stroke.
Journal of Neurology Neurosurgery & PsychiatryAntithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.
208 Citations1993Peter Sandercock, Angelique GM van den Belt +2 more
Early heparin treatment might be associated with substantial reductions in deep venous thrombosis (and probably also pulmonary embolism) and possibly a one fifth reduction in mortality (equivalent to the avoidance of 20-40 early deaths per thousand patients treated.)
Annals of Internal MedicineIntravenous Heparin for the Prevention of Stroke Progression in Acute Partial Stable Stroke: A Randomized Controlled Trial
203 Citations1986R. J. Duke, RALPH F. BLOCH +4 more
Results of this study do not support the use of intravenous heparin to treat patients who have had acute partial stroke.
The LancetDOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE
201 Citations1987A. G. G. Turpie, Jack Hirsh +8 more
Prophylaxis was started within 7 days of the onset of stroke with a loading dose of 1000 anti-factor-Xa units intravenously followed by a fixed dose of 750 anti- Factor Xa units twice a day subcutaneously; it was continued for 14 days or until hospital discharge, if earlier.
HaemostasisPrevention of Deep Vein Thrombosis in Elderly Medical In-Patients by a Low Molecular Weight Heparin: A Randomized Double-Blind Trial
200 Citations2009Rachel Dahan, D Houlbert +5 more
In conclusion, LMW heparin appears of value in preventing the occurrence of DVT in an unselected elderly in-patient population.
The LancetLOW-DOSE HEPARIN AS A PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ACUTE STROKE
198 Citations1977Sharon McCarthy, Derrick Robertson +3 more
A trial of subcutaneous low-dose heparin in the prevention of deep-vein thrombosis was carried out in elderly patients admitted to hospital after an acute stroke and a statistically significant reduction was observed inDeep Vein ThromBosis as assessed by isotope leg scanning.
Cochrane Database of Systematic ReviewsAnticoagulation for cerebral venous sinus thrombosis
193 Citations2011Jonathan M. Coutinho, Sebastiaan F. de Bruijn +2 more
Anticoagulant treatment for cerebral venous sinus thrombosis appeared to be safe and was associated with a potentially important reduction in the risk of death or dependency which did not reach statistical significance.
Annals of Internal MedicineVenous Thromboembolism Prophylaxis in Hospitalized Medical Patients and Those With Stroke: A Background Review for an American College of Physicians Clinical Practice Guideline
162 Citations2011Frank A. Lederle, Dylan M. Zylla +2 more
Hemparin prophylaxis had no significant effect on mortality, may have reduced PE in medical patients and all patients combined, and led to more bleeding and major bleeding events, thus resulting in little or no net benefit.
Age and AgeingLOW-DOSE SUBCUTANEOUS HEPARIN IN THE PREVENTION OF DEEP-VEIN THROMBOSIS AND PULMONARY EMBOLI FOLLOWING ACUTE STROKE
160 Citations1986Sharon McCarthy, Joel Turner
Low-dose calcium heparin given subcutaneously following acute stroke reduced the number of deep-vein thromboses, pulmonary emboli and deaths without increasing the numberof haemorrhagic strokes in this study.
Cochrane Database of Systematic ReviewsLow-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke
135 Citations2017Peter Sandercock, Tze Shin Leong
Treatment with a LMWH or heparinoid after acute ischaemic stroke appears to decrease the occurrence of DVT compared with standard UFH, but there are too few data to provide reliable information on their effects on other important outcomes, including functional outcome, death and intracranial haemorrhage.
The Lancet NeurologyTargeted use of heparin, heparinoids, or low-molecular-weight heparin to improve outcome after acute ischaemic stroke: an individual patient data meta-analysis of randomised controlled trials
124 Citations2013William Whiteley, Harold P. Adams +7 more
No evidence that patients with ischaemic stroke who were at higher risk of thrombotic events or lower risk of haemorrhagic events benefited from heparins was found, and guidelines for routine or selective use of heparin in stroke should be revised.
PubMedLow molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.
120 Citations1998
Emergent administration of the antithrombotic agent, ORG 10172, is not associated with an improvement in favorable outcome at 3 months, and this trial concluded that low molecular weight heparinoids might be effective in reducing unfavorable outcomes following ischemic stroke.
StrokeIntravenous Heparin Started Within the First 3 Hours After Onset of Symptoms as a Treatment for Acute Nonlacunar Hemispheric Cerebral Infarctions
119 Citations2005M. Camerlingo, Pietro Salvi +4 more
Intravenous heparin sodium could be of help in the earliest treatment of acute nonlacunar hemispheric cerebral infarction, even keeping into account an increased frequency of intracranial symptomatic brain hemorrhages.
StrokeArgatroban Anticoagulation in Patients With Acute Ischemic Stroke (ARGIS-1)
114 Citations2004Marian P. LaMonte, Marshall Nash +5 more
It is suggested that argatroban provides safe anticoagulation in acute ischemic stroke, warranting future studies powered to evaluate its efficacy and more precisely estimate event rates.
HaemostasisProphylaxis of Deep Venous Thrombosis with a Low-Molecular-Weight Heparin (Kabi 2165/Fragmin®) in Stroke Patients
111 Citations2009Martin H. Prins, R.G. Gelsema +3 more
BMJStatistics Notes: Interaction 1: heterogeneity of effects
105 Citations1996D G Altman, John N. S. Matthews
In several types of study the authors may want to examine the consistency of an observed relation across two or more subgroups of the individuals studied, and the examination of the heterogeneity of an observation effect, such as treatment benefit in a clinical trial, across subsets of individuals.
PubMedA double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke.
103 Citations1990Per Morten Sandset, Trond Dahl +4 more
It is concluded that LMW heparin in the dose range studied did not provide efficient prophylaxis against DVT in patients with acute ischemic stroke.
Seminars in Thrombosis and HemostasisEffect of the Thrombin Inhibitor Argatroban in Acute Cerebral Thrombosis
95 Citations1997Shotai Kobayashi, Yoshiaki Tazaki
It was found that administration of the drug in the early stage of the disease gave better results, and this indicates that argatroban is an effective and safe drug for the treatment of acute cerebral thrombosis.
The Journal of Alternative and Complementary MedicineInteraction Between Warfarin and <i>Panax ginseng</i> in Ischemic Stroke Patients
87 Citations2008Sang‐Hun Lee, Young-min Ahn +3 more
This study suggests that coadministration of P. ginseng and warfarin in ischemic stroke patients does not influence the pharmacologic action of warFarin.
Archives of Physical Medicine and RehabilitationDeep vein thrombosis: Prevention in stroke patients during rehabilitation
81 Citations1995Georgia Pambianco, Trevor J. Orchard +1 more
The results suggest that the longer a patient remains without DVT prophylaxis after a stroke, the greater the risk of developing DVT and this supports early prophYLaxis before rehabilitation.
StrokeSequential computerized tomographic appearance of strokes.
80 Citations1983A. M. Hakim, A Ryder-Cooke +1 more
In patients showing hemorrhagic infarction before anticoagulants, follow-up scans obtained after the administration of anticoAGulants revealed resolution of the hemorrhagic aspect, and the CT appearance of hemorrhagicinfarction is likely to occur twice as frequently in CT scans of strokes presumed embolic than in those presumed thrombotic.
Cochrane Database of Systematic ReviewsFibrinogen depleting agents for acute ischaemic stroke
74 Citations2012Zilong Hao, Ming Liu +4 more
The current evidence is promising but not yet sufficiently robust to support the routine use of fibrinogen depleting agents for the treatment of acute ischaemic stroke.
Cochrane Database of Systematic ReviewsAnticoagulants for acute ischaemic stroke
73 Citations2004Gordon Gubitz, Peter Sandercock +1 more
Immediate anticoagulant therapy in patients with acute ischaemic stroke is not associated with net short- or long-term benefit, and the data from this review do not support the routine use of any type of anticoaggulant in acute ishaemic stroke.
StrokeUse of Intravenous Heparin by North American Neurologists
61 Citations2002Ahmad Al-Sadat, Mohammad Sunbulli +1 more
US neurologists were significantly more likely than Canadian neurologists to use intravenous heparin for patients with acute ischemic stroke, and Fears regarding medicolegal consequences may partially explain the treatment disparity.
Annals of Internal MedicineA Long-term Study of Cerebral Vascular Disease
50 Citations1961Sigmund N. Groch, ELLEN MCDEVITT +1 more
A study of cerebral vascular disease, utilizing the patients on the wards of the Second Medical and Neurological Services and the First Medical Service, has been in pro...
Acta Neurologica ScandinavicaEffects of low-dose subcutaneous heparin on the occurrence of deep vein thrombosis in patients with ischemic stroke
47 Citations2009H. J. Gelmers
The effectiveness of low‐dose subcutaneous heparin in the prophylaxis of deep vein thrombosis in patients with ischemic stroke was investigated in an unblinded controlled study.
Blood Coagulation & FibrinolysisThrombin inhibition in the acute phase of ischaemic stroke using argatroban
40 Citations1995Kazuomi Kario, Kenji Kodama +2 more
D-dimer levels were significantly reduced in the argatroban group on days 2 and 7 after admission when compared with the placebo group, indicating that haemostatic activation occurred in acute ischaemic stroke was effectively blocked by argatro Ban.
La Revue de Médecine InternePrévention des thromboses veineuses profondes des membres inférieurs par une fraction d'héparine de très bas poids moléculaire (CY 222) chez des patients porteurs d'une hémiplégie secondaire à un infarctus cérébral: étude pilote randomisée (30 patients)
40 Citations1990Antoine Élias, L Milandre +8 more
The effectiveness and safety of a very low molecular weight heparin fraction were evaluated in the prevention of deep-vein thrombosis in patients confined to bed due to hemiplegia consecutive to a recent cerebral infarction and numerous standard laboratory tests confirmed that CY 222 was well tolerated.
Archives of NeurologyAnticoagulant Therapy
40 Citations1963Fletcher McDowell
This study was designed to test the thesis that anticoagulant therapy is of value in the prevention of further thrombo-embolic phenomena such as second strokes, pulmonary emboli, and myocardial infarction in patients with an established stroke.
American Journal of Physical Medicine & RehabilitationDEEP VEIN THROMBOSIS IN REHABILITATING STROKE PATIENTS Incidence, Risk Factors and Prophylaxis
32 Citations1991Meena Desmukh, Mark Bisignani +2 more
It is concluded that ultrasound is effective for DVT detection in the rehabilitation setting, and two-thirds of such cases are detectable on admission, and the three treatments were adjusted-dose heparin, external pneumatic compression and functional electrical muscle stimulation.
Acta Neurologica ScandinavicaEvaluation of anticoagulants in patients with cerebral infarction with slight to moderate neurological deficit
29 Citations1983Sven‐Erik Eriksson, Hans Link
In a non‐randomized controlled study carried out on 238 hospitalized patients with cerebral infarction, anticoagulant treatment (AC) was compared with the natural course in the prevention of transient ischemic attacks (TIA), cerebral infARction, stroke, stroke or death.
DMW - Deutsche Medizinische WochenschriftProphylaxe venöser Thrombosen bei frischem ischämischem zerebrovaskulärem Insult: Doppelblindstudie mit Heparin-Dihydergot<sup>®</sup>
28 Citations2008B. Czechanowski, F Heinrich
It is shown that a prophylactic regimen of the type described is a practicable and effective measure after recent ischaemic cerebrovascular accident and heart failure, reduction of muscle tone, muscular power and level of consciousness favoured thrombosis.
Journal of Neurology Neurosurgery & PsychiatryStudy design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study.
25 Citations1996Peter Sandercock, Professor L Provinciali +137 more
Recruitment rates in the pilot study indicated that if about 200 hospitals participated, recruitment could be completed by 1997 and reliable evidence on the balance of risk and benefit of early antithrombotic therapy might require a study with more than 20,000 patients.
Journal of Neurology Neurosurgery & PsychiatryTrial of long-term anticoagulant therapy in the treatment of small stroke associated with a normal carotid arteriogram.
21 Citations1975P. Bradshaw, Sharon L. Brennan‐Olsen
There was a reduced incidence of neurological episodes during the administration of anticoagulant therapy but, after treatment was discontinued, there was no significant difference between the two groups.
Cochrane Database of Systematic ReviewsFibrinogen depleting agents for acute ischaemic stroke
20 Citations2003Ming Liu, Carl Counsell +2 more
Fibrinogen depleting agents are promising in patients with acute ischaemic stroke, however more data, particularly ESTAT data, are needed before more reliable conclusions can be drawn.
CirculationA Cooperative Study of Cerebrovascular Disease
19 Citations1959Ellen McDevitt, Sigmund N. Groch +1 more
A preliminary report of a cooperative study of cerebrovascular vascular accidents with anticoagulant agents is presented and the methodology and protocol of the study, problems inherent in it, and preliminary findings of the first two years are indicated.
Clinical and Applied Thrombosis/HemostasisOptimal Dosing of Intravenous Unfractionated Heparin Bolus in Transient Ischemic Attack or Stroke
8 Citations2008Kyusik Kang, Dong Wook Kim +2 more
Patients treated with the low bolus dose (30 U/kg) were more often within the therapeutic range for activated partial thromboplastin time at two hours after the initial bolus than patients treating with the other regimens.
NosotchuEffects of urokinase and heparin on hemorrhagic infarction, recanalization, recurrence - Analysis of 111 cases with middle cerebral artery occlusion on an acute stage in a prospective controlled trial.
8 Citations1989Takashi Tsuchiya, Kunihiko Fujikake +1 more
NosotchuA study on clinical effects of the combinated therapy of urokinase and heparin for acute lacunar infarcts in a prospective controlled trial.
7 Citations1990Takashi Tsuchiya, Kunihiko Fujikake +1 more
PubMed[Mesoglycan in acute focal cerebral ischemia].
7 Citations1990Giuseppe Cazzato, Marino Zorzon +3 more
The mesoglycan was very well tolerated and no side-effects were observed during the treatment, as their changes after thirty days of therapy were in the normal range.
Zhōnghuá yàoxué zázhìClinical study of low-molecular-weight heparin calcium and aspirin therapy on acute cerebral infarction
5 Citations2005Wenbo Ren
The earlier treatment of acute cerebral infarction with low-molecular-weight heparin calcium and aspirin is safe and effective.
Annals of Internal MedicineHeparin in Acute Partial Stable Stroke
4 Citations1987E.A. Loeliger
Excerpt To the editor: Duke and colleagues present evidence that anticoagulation with heparin does not improve the short-term prognosis in patients with acute partial stable stroke.
Clinical Drug InvestigationInitial 3-Weeks’ Apixaban Versus Dual-Antiplatelet Therapy (Clopidogrel and Aspirin) Followed by Clopidogrel Alone in High-Risk Patients with Acute Non-Disabling Cerebrovascular Events (ADANCE): Study Protocol for a Randomized Controlled Trial
3 Citations2014Fang Yang, Hui Lei +4 more
The ADANCE trial was designed to observe the effects of apixaban on recurrent stroke after TIA or minor stroke, and the results should better guide the selection of anticoagulant or dual-antiplatelet therapy for patients with acute Tia or minor ischemic stroke.
Pharmaceutical Care and ResearchThe clinical observation of low molecular weight heparin calcium in treating the patients with acute cerebral infarction
2 Citations2004Jun Shi
The improvement of scores of nervous system damage and the changes of hemorheological indexes of the treatment group were better than those of the control group, but the platelet count, the bleeding time and coagulation time had no evident changes.
…